Literature DB >> 28710115

Acromegaly is associated with increased cancer risk: a survey in Italy.

Massimo Terzolo1, Giuseppe Reimondo2, Paola Berchialla3, Emanuele Ferrante4, Elena Malchiodi4, Laura De Marinis5, Rosario Pivonello6, Silvia Grottoli7, Marco Losa8, Salvatore Cannavo9, Diego Ferone10, Marcella Montini11, Marta Bondanelli12, Ernesto De Menis13, Chiara Martini14, Efisio Puxeddu15, Antonino Velardo16, Alessandro Peri17, Marco Faustini-Fustini18, Patrizia Tita19, Francesca Pigliaru20, Giulia Peraga1, Giorgio Borretta21, Carla Scaroni22, Nicoletta Bazzoni23, Antonio Bianchi5, Alessandro Berton7, Andreea Liliana Serban4, Roberto Baldelli24, Letizia Maria Fatti25, Annamaria Colao6, Maura Arosio4.   

Abstract

It is debated if acromegalic patients have an increased risk to develop malignancies. The aim of the present study was to assess the standardized incidence ratios (SIRs) of different types of cancer in acromegaly on a large series of acromegalic patients managed in the somatostatin analogs era. It was evaluated the incidence of cancer in an Italian nationwide multicenter cohort study of 1512 acromegalic patients, 624 men and 888 women, mean age at diagnosis 45 ± 13 years, followed up for a mean of 10 years (12573 person-years) in respect to the general Italian population. Cancer was diagnosed in 124 patients, 72 women and 52 men. The SIRs for all cancers was significantly increased compared to the general Italian population (expected: 88, SIR 1.41; 95% CI, 1.18-1.68, P < 0.001). In the whole series, we found a significantly increased incidence of colorectal cancer (SIR 1.67; 95% CI, 1.07-2.58, P = 0.022), kidney cancer (SIR 2.87; 95% CI, 1.55-5.34, P < 0.001) and thyroid cancer (SIR 3.99; 95% CI, 2.32-6.87, P < 0.001). The exclusion of 11 cancers occurring before diagnosis of acromegaly (all in women) did not change remarkably the study outcome. In multivariate analysis, the factors significantly associated with an increased risk of malignancy were age and family history of cancer, with a non-significant trend for the estimated duration of acromegaly before diagnosis. In conclusion, we found evidence that acromegaly in Italy is associated with a moderate increase in cancer risk.
© 2017 Society for Endocrinology.

Entities:  

Keywords:  GH; IGF1; acromegaly; cancer

Mesh:

Year:  2017        PMID: 28710115     DOI: 10.1530/ERC-16-0553

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  17 in total

1.  Predictors of colonic pathologies in active acromegaly: single tertiary center experience.

Authors:  Raim Iliaz; Sema Ciftci Dogansen; Seher Tanrikulu; Gulsah Yenidunya Yalin; Bilger Cavus; Mine Gulluoglu; Filiz Akyuz; Sema Yarman
Journal:  Wien Klin Wochenschr       Date:  2018-07-30       Impact factor: 1.704

2.  Pituitary neuroendocrine tumors and differentiated thyroid cancer: do metabolic and inflammatory risk factors play roles?

Authors:  G Cortês Nascimento; A G P de Araujo Cortês Nascimento; C de Maria Ribeiro Veiga Parente; V P Rodrigues; R S de Sousa Azulay; V C de Carvalho Rocha; S da Silva Pereira Damianse; M Magalhães; M Dos Santos Faria; M B Gomes
Journal:  J Endocrinol Invest       Date:  2020-07-17       Impact factor: 4.256

3.  Cancer prevalence and cancer screening in patients with acromegaly: a single center experience.

Authors:  Elif Tutku Durmuş; Ayşegül Atmaca; Ramis Çolak; Buğra Durmuş
Journal:  Endocrine       Date:  2022-05-24       Impact factor: 3.925

Review 4.  Acromegaly and Colorectal Neoplasm: An Update.

Authors:  Leandro Kasuki; Bernardo Maia; Mônica R Gadelha
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-20       Impact factor: 6.055

Review 5.  Acromegaly in the elderly patients.

Authors:  Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2020-02-14       Impact factor: 3.633

6.  Increased risk of preneoplastic colonic lesions and colorectal carcinoma in acromegaly: multicenter case-control study.

Authors:  Maria Florencia Battistone; Karina Miragaya; Amelia Rogozinski; Monica Agüero; Analia Alfieri; Maria Carolina Ballarino; Laura Boero; Karina Danilowicz; Sabrina Diez; Marina Donoso; Patricia Fainstein-Day; Alejandra Furioso; Natalia Garcia-Basavilbaso; Mariela Glerean; Debora Katz; Monica Loto; Susana Mallea-Gil; Marcela Martinez; Maria Isabel Sabate; Marisa Servidio; Patricia Slavinsky; Graciela Stalldecker; Soledad Sosa; Grabriela Szuman; Julieta Tkatch; Ignacio Caldo; Daniela Lubieniecki; Mirtha Guitelman
Journal:  Pituitary       Date:  2020-10-15       Impact factor: 4.107

7.  Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study.

Authors:  Giulia Carosi; Alessandra Mangone; Elisa Sala; Giulia Del Sindaco; Roberta Mungari; Arianna Cremaschi; Emanuele Ferrante; Maura Arosio; Giovanna Mantovani
Journal:  Eur J Endocrinol       Date:  2021-07-01       Impact factor: 6.664

Review 8.  Acromegaly and male sexual health.

Authors:  Gianmaria Salvio; Marianna Martino; Giancarlo Balercia; Giorgio Arnaldi
Journal:  Rev Endocr Metab Disord       Date:  2022-04-01       Impact factor: 9.306

Review 9.  Targeting growth hormone function: strategies and therapeutic applications.

Authors:  Man Lu; Jack U Flanagan; Ries J Langley; Michael P Hay; Jo K Perry
Journal:  Signal Transduct Target Ther       Date:  2019-02-08

10.  Growth hormone upregulates the pro-tumorigenic galectin 1 in mouse liver.

Authors:  María L Bacigalupo; Verónica G Piazza; Nadia S Cicconi; Pablo Carabias; Andrzej Bartke; Yimin Fang; Ana I Sotelo; Gabriel A Rabinovich; María F Troncoso; Johanna G Miquet
Journal:  Endocr Connect       Date:  2019-08-01       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.